Innate Pharma SA annual free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Innate Pharma SA Free Cash Flow (FCF) History (IPHA)
Innate Pharma SA reported −€52.9M in free cash flow for fiscal 2025, a decrease of €45.6M from the previous fiscal year, with a free cash flow margin of −587.40%.
View full Innate Pharma SA company overviewInnate Pharma SA free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −€52.9M | −€45.6M | — | −587.40% |
| 2024 | 2024-12-31 | −€7.3M | €25.6M | — | −36.22% |
| 2023 | 2023-12-31 | −€32.9M | −€13.2M | — | −53.39% |
| 2022 | 2022-12-31 | −€19.7M | €39.7M | — | −34.14% |
| 2021 | 2021-12-31 | −€59.4M | −€6.7M | — | −240.40% |
| 2020 | 2020-12-31 | −€52.7M | −€86.3M | — | −75.49% |
| 2019 | 2019-12-31 | €33.7M | €67.1M | — | +39.38% |
| 2018 | 2018-12-31 | −€33.4M | €17.6M | — | −35.55% |
| 2017 | 2017-12-31 | −€51.0M | — | — | −115.88% |
Innate Pharma SA quarterly free cash flow
No reported data
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|
Innate Pharma SA free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −€52.7M to −€52.9M, a net decrease of €221,000.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Innate Pharma SA filings at SEC.gov ↗